Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Excipients list used in dexamethasone creams?
Mebendazole ingredients?
Dabrafenib and trametinib price?
Guselkumab loss of exclusitivy?
How does iron rich food intake impact lipitor's efficacy?

Is dorzolamide eye drops still on the market in california?

See the DrugPatentWatch profile for dorzolamide

Short answer:
Yes—dorzolamide eye drops are still available in California, both under brand names and as generics.

What is dorzolamide?

  • Drug class: Carbonic anhydrase inhibitor (CAI).
  • Use: Lower intra‑ocular pressure (IOP) in conditions such as glaucoma and ocular hypertension.
  • Common brand names:
    • Trusopt (first and most widely known brand)
    • Trusopt® 2% (dorzolamide 2% solution)
    • Dorzolamide 2% (generic name sold by many manufacturers)

Availability in California

Status Details
Brand‑name Trusopt Available from most major pharmacies (Walgreens, CVS, Rite Aid, etc.), eye‑care specialty shops, and online pharmacies that ship to California.
Generic dorzolamide 2% Widely stocked by generic drug manufacturers (e.g., Teva, Mylan, Sandoz). Usually cheaper and available in 5‑mL vials or pre‑filled pens.
Specialty pharmacy distribution Many eye‑specialty pharmacies (e.g., EyeCareRx, Eyeline Pharmacy) offer both brand and generic formulations, and can ship across California.
Prescription requirement Like all ophthalmic medications, a valid prescription from a licensed provider is required.
Insurance coverage Most major insurance plans (Blue Cross, Blue Shield, Medicare Part D, etc.) cover dorzolamide. Check your specific plan for copays or prior‑authorization requirements.

Why you might still need it

  • Glaucoma treatment – Often used as part of a multi‑drug regimen.
  • Ocular hypertension – Reduces IOP to prevent optic nerve damage.
  • Post‑surgery IOP control – Sometimes prescribed after cataract or glaucoma surgery.

How to obtain it

  1. Get a prescription from an ophthalmologist, optometrist, or primary‑care clinician.
  2. Ask the pharmacist about the cost: generic is usually about 30–60% cheaper than the brand.
  3. Check for drug discount programs – e.g., RxAssist, GoodRx, or manufacturer coupons (often available for Trusopt).
  4. Verify shipping if ordering online—ensure the pharmacy is licensed to deliver medications to California.

Recent regulatory notes

  • FDA status: The FDA has not withdrawn dorzolamide from the market; it remains approved for ophthalmic use.
  • Safety profile: No major safety alerts have been issued in the past 5 years. The typical side‑effect profile includes mild burning, itching, or transient blurred vision.
  • Manufacturing changes: Some manufacturers have updated excipient formulations; always check the product labeling for any changes if you have sensitivities.

Bottom line

If you’re currently prescribed dorzolamide or are looking to start therapy, you can confidently obtain it in California. Whether you choose the brand‑name Trusopt or a generic equivalent, the product remains in the market, fully approved, and covered by most insurance plans. If you have any specific concerns—like side effects or cost—talk to your prescribing eye doctor or pharmacist; they can help you find the most affordable, suitable option.



Other Questions About Dorzolamide :

dorzolamide brand name Dorzolamide brand name? Dorzolamide hydrochloride market? Dorzolamide generic? Dorzolamide timolol discount? Dorzolamide eye drops manufacturer? Dorzolamide timolol pf coupon?

AI-Drug Label Prescribing Information Alignment Report

78
78%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The AI response correctly reflects the FDA label excerpts for indication and dosing (twice daily) and does not present contradictions based on the provided text. However, it also includes meta-statements about verification/absence of contraindications/boxed warnings that are not actually supported by the excerpts shown, limiting audit certainty.

Category Scores

Indication
92
Excellent
Dosage
85
Good

Accurate Statements

Dorzolamide hydrochloride and timolol maleate ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
INDICATIONS AND USAGE excerpt.
Dosing as one drop ... in the affected eye(s) two times daily.
DOSAGE AND ADMINISTRATION excerpt.
If more than one topical ophthalmic drug is being used, administer at least five minutes apart.
DOSAGE AND ADMINISTRATION excerpt.

Unsupported Statements

The provided labeling clearly identifies... Contraindications and Warnings reference timolol (beta-blocker) and dorzolamide (sulfonamide/carbonic anhydrase inhibitor).
No contraindications or warnings text is included in the provided excerpts, so this specific claim cannot be verified from the supplied label text.
Supported: yes; Contradicted: no; Mentioned: yes (and that specific user claims were not provided).
The assessment is not grounded in explicit mapping to a concrete user claim; the response also relies on section references without including the underlying contraindications/warnings content.
No specific user claim was provided in the message to map directly; however, the provided evaluation text indicates the indication and twice-daily dosing align with the label excerpts.
The message does not contain a single explicit user claim to map; alignment is asserted generally rather than demonstrated against a specific claim string.

Contradictions

Important Omissions

No evaluation of contraindications/boxed warnings/warnings/precautions/drug interactions/adverse reactions is performed, despite the response implying such sections were 'clearly' referenced.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The only substantive clinical content verified from the provided excerpts is the indication and twice-daily dosing, which align with label text. Potential risk is limited to uncertainty introduced by unsupported assertions about contraindications/warnings and the scope of label verification.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Unsupported claims about contraindications/warnings content and an overconfident verification statement not supported by the included excerpts.

Suggested Improvement
Limit verification to the exact label text provided (indications and dosage excerpts) and remove or qualify statements about contraindications/warnings unless their corresponding label excerpts are included.